Revenue
2016
2017
2018
2019
2020
2021
2022
2023
Perspective Therapeutics, Inc. (CATX)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $1.4M | $10.8M | $10.1M | $9.7M | $7.3M | $5.9M | $4.8M | $4.8M | — | — | — | — | — |
| Gross profit | — | — | $1.4M | $0 | $5.1M | $5.1M | $3.0M | $1.8M | $838,000 | $129,000 | $167,000 | −$196,471 | $150,176 | $703,204 | $1.2M |
| Research & development | $84.2M | $41.6M | $21.3M | $850,000 | $1.4M | $1.1M | $1.5M | $1.7M | $965,000 | $528,000 | $615,000 | $668,803 | $627,107 | $780,579 | $981,186 |
| Operating expenses | $114.4M | $92.3M | $42.4M | $6.4M | $8.6M | $8.6M | $8.3M | $8.6M | $7.1M | $5.2M | $4.5M | $4.4M | $4.2M | $4.3M | $4.1M |
| Operating income | −$113.6M | −$90.9M | −$40.9M | −$6.4M | −$3.4M | −$3.5M | −$5.3M | −$6.7M | −$6.3M | −$5.1M | −$4.3M | −$4.6M | −$4.1M | −$3.6M | −$3.0M |
| EBITDAderived | −$110.3M | −$88.6M | −$40.0M | −$6.2M | −$3.3M | −$3.3M | −$5.1M | −$6.6M | −$6.2M | −$4.6M | −$3.8M | −$3.9M | −$3.3M | −$2.8M | −$2.1M |
| Net income | −$103.1M | −$79.3M | −$46.5M | −$7.3M | −$3.4M | −$3.4M | −$5.1M | −$6.7M | −$6.2M | −$4.7M | −$3.7M | −$6.0M | −$3.9M | −$3.5M | −$2.8M |
| Basic EPSper diluted share | -$1.40 | -$1.23 | -$1.74 | -$0.05 | -$0.03 | -$0.05 | -$0.08 | -$0.12 | -$0.11 | -$0.09 | -$0.07 | -$0.16 | -$0.11 | -$0.12 | -$0.11 |
| Diluted EPSper diluted share | -$1.40 | -$1.23 | -$1.74 | — | -$0.03 | -$0.05 | -$0.08 | -$0.12 | -$0.11 | -$0.09 | -$0.07 | -$0.16 | -$0.11 | -$0.12 | -$0.11 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Nov 13, 2025Form 4 | Hunt Jonathan RobertChief Accounting Officer | BuyCommon Stock | 11.0K | $2.03 | $22.3K | 59.8K |
| Nov 12, 2025Form 4 | Williamson Robert F IIIDirector | BuyCommon Stock · indirect | 9.5K | $2.10 | $19.9K | 9.9K |
| Mar 31, 2025Form 4 | Williamson Robert F IIIDirector | BuyCommon Stock | 38.1K | $2.14 | $81.6K | 109.0K |
| Mar 31, 2025Form 4 | Woods Lori ADirector | BuyCommon Stock · indirect | 23.5K | $2.13 | $50.0K | 183.5K |
| Mar 28, 2025Form 4 | Spoor Johan M.Chief Executive Officer | BuyCommon Stock · indirect | 4.7K | $2.21 | $10.3K | 4.7K |